Physician profile
Ramon Colina
NPI 1871511386
$5,320.74
in general payments reported to CMS, 2019-2025
23 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $871 · 2021: $1,270 · 2022: $1,221 · 2023: $687 · 2024: $256 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,089.91 | 2019-2024 | Skyrizi, Rinvoq, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $967.57 | 2019-2023 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $649.34 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.43 | 2019-2023 | Entyvio |
| Genzyme Corporation | $229.12 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $163.39 | 2021-2023 | |
| Janssen Biotech, INC. | $125.00 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $121.92 | 2023 | Zeposia |
| Redhill Biopharma INC. | $120.97 | 2020-2022 | |
| Celgene Corporation | $110.60 | 2022-2023 | Zeposia |
| Allergan, INC. | $101.73 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $73.44 | 2023 | Dupixent |
| Gilead Sciences, INC. | $56.60 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $55.57 | 2019-2021 | |
| Pfizer INC. | $52.19 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $42.43 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $31.86 | 2022-2023 | Dificid |
| Glaxosmithkline, LLC. | $24.46 | 2024 | Shingrix, Arexvy |
| Ferring Pharmaceuticals INC. | $21.50 | 2022 | |
| Amag Pharmaceuticals, INC. | $16.66 | 2021 | |
| Vivus LLC | $14.25 | 2022 | |
| Evoke Pharma, INC. | $12.44 | 2021 | |
| Romark Laboratories, Lc | $2.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Colina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.